Vivos Therapeutics, Inc. 8-K

What Happened
Vivos Therapeutics, Inc. (VVOS) announced it entered an Exchange Agreement with Streeterville Capital, LLC on June 5, 2026, under which Streeterville agreed to exchange a portion of the Company’s outstanding debt for shares of the Company’s preferred stock and common stock. On June 18, 2026 the Company and Streeterville signed a Letter Agreement extending the outside date to complete a qualifying financing from June 15, 2026 to August 31, 2026. The company issued a press release about the Letter Agreement on June 22, 2026.

Key Details

• Exchange Agreement dated June 5, 2026 with Streeterville Capital, LLC to convert part of the Company’s indebtedness into preferred and common stock.
• Letter Agreement dated June 18, 2026 extends the deadline to secure a qualifying financing to August 31, 2026 (previous deadline: June 15, 2026).
• Required qualifying financing: at least $2,600,000.
• Related documents (Exchange Agreement, Letter Agreement, press release) are filed as exhibits to the 8-K.

Why It Matters
This is a financing and balance-sheet action: converting debt into equity reduces liabilities and postpones immediate cash fundraising pressure, while the extension gives the company more time to secure the required $2.6M financing. Investors should watch for whether the financing is completed by Aug 31, 2026 and for any dilution from the issuance of preferred and common shares as part of the debt exchange.